The RANKL/RANK pathway is often overexpressed in cancers of the breast, prostate, endometrium, cervix, stomach, esophagus, bladder, and thyroid and this is correlated with poor prognosis [11,17,23,34,50,51,52,53,54,55,56,57,58]. Here, TNFRSF11A is linked to breast cancer.